Detail akcie Astra Zeneca online

Business Summary: AstraZeneca PLC is a United Kingdom-based science-led biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of prescription medicines. The Company operates across therapy areas, including Oncology; Cardiovascular, Renal and Metabolism (CVRM); Respiratory and Immunology (R&I); Vaccines and Immune Therapies (V&I), and Rare Disease. In the Oncology area, its key products include Tagrisso, Imfinzi, Calquence, Lynparza, and Enhertu. The key products of CVRM area include Farxiga/Forxiga, Brilinta/Brilique, Crestor, and Lokelma. In the R&I area, the key products are Symbicort, Fasenra, Breztri/Trixeo, and Tezspire. In the V&I Therapies area, the products are Beyfortus and FluMist. The products in the Rare Disease area are Ultomiris, Soliris, Strensiq, and Koselugo. It has about 191 projects in its development pipeline, including 19 new molecular entities (NMEs) in the late-stage pipeline. The Company distributes its products in over 125 countries.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2025, AstraZeneca plc revenues increased 9% to $58.74B. Net income increased 45% to $10.23B. Revenues reflect Imfinzi segment increase of 29% to $6.06B, Ultomiris segment increase of 20% to $4.72B, Farxiga segment increase of 10% to $8.4B, United States segment increase of 10% to $23.97B, Other European Countries segment increase of 18% to $4.32B, Other Asia.